Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Icotrokinra pediatric long-term extension study
2026-526290-41-00Phase 3Authorised
- Sponsor
- Janssen Pharmaceutical
- Start
- Oct 2026
- Modality
- Peptides
- Countries
- 7
01
Overview
Phase 3, open-label, single-arm trial of icotrokinra in Disorders of Immunity, sponsored by Janssen Pharmaceutical. Primary endpoints: Adverse events, Adverse events of special interest and 1 more. Planned start Oct 2026; status: authorised.
02
Drugs
icotrokinra
03
Conditions
Disorders of Immunity
Beyond the preview
Go deeper on 2026-526290-41-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2026-526290-41-00.